Evidence supporting the hypothesis that raising plasma levels of high-density lipoprotein (HDL) cholesterol could be cardioprotective has fuelled intense efforts to develop HDL-targeted therapies, but several recent clinical trial failures have introduced controversy. Kingwell and colleagues discuss the current understanding of the HDL hypothesis, considering what has been learned, what remains to be tested and how this knowledge could be used in the development of novel therapies.
- Bronwyn A. Kingwell
- M. John Chapman
- Norman E. Miller